Advertisement
Singapore markets close in 3 hours 37 minutes
  • Straits Times Index

    3,307.80
    +7.80 (+0.24%)
     
  • Nikkei

    38,645.15
    +12.13 (+0.03%)
     
  • Hang Seng

    18,002.93
    -332.39 (-1.81%)
     
  • FTSE 100

    8,272.46
    +67.35 (+0.82%)
     
  • Bitcoin USD

    64,515.05
    -763.08 (-1.17%)
     
  • CMC Crypto 200

    1,354.27
    -28.39 (-2.05%)
     
  • S&P 500

    5,473.17
    -13.86 (-0.25%)
     
  • Dow

    39,134.76
    +299.90 (+0.77%)
     
  • Nasdaq

    17,721.59
    -140.64 (-0.79%)
     
  • Gold

    2,376.10
    +7.10 (+0.30%)
     
  • Crude Oil

    82.34
    +0.17 (+0.21%)
     
  • 10-Yr Bond

    4.2540
    +0.0370 (+0.88%)
     
  • FTSE Bursa Malaysia

    1,596.24
    +3.55 (+0.22%)
     
  • Jakarta Composite Index

    6,933.09
    +113.77 (+1.67%)
     
  • PSE Index

    6,242.28
    -102.28 (-1.61%)
     

Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc.

CONSHOHOCKEN, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024, and will present at 8:40 A.M. ET.

The presentation will be webcast live and may be accessed here or by visiting Madrigal’s website’s Investor Relations Events page. A replay of the webcast will be available after the event.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH. For more information, visit www.madrigalpharma.com.

Investor Contact
Tina Ventura, Madrigal Pharmaceuticals, Inc., IR@madrigalpharma.com

Media Contact
Christopher Frates, Madrigal Pharmaceuticals, Inc., media@madrigalpharma.com